2.4 Drug information extraction
We evaluated 11 pulmonary vasodilators listed in Supplementary Table S1.
The identification numbers of PAH patients treated with these drugs were
extracted from the DRUG table. In this study, the PAH patients with
concomitant use of PAH-specific vasodilators targeting the same
biological pathways were excluded. We also evaluated supportive therapy
for PAH, including oxygen therapy, anticoagulant therapy with warfarin
or direct oral anticoagulant (DOAC), including apixaban, edoxaban, and
rivaroxaban, and diuretic therapy with tolvaptan. Drugs reported in the
DRUG table are categorized into ”suspected drug”, ”concomitant drug”,
and ”interacting drug”. We employed drug information reported as
”suspected drug” and ”concomitant drug” for analyses in this study.